文献速递脊柱关节炎

重复MRI在评估中轴型脊柱关节炎治疗无反应中的应用:来自两个大型风湿病中心的数据

Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres.
PubMed 文献 · RMD Open · 2025-10-17

结果显示54.7%的MRI有活动性炎症证据,且伴有活动性炎症的患者更可能升级治疗(59.3% vs 23.2%)。作者认为MRI可用于评估疾病活动度并直接影响临床治疗决策。

要点

  • 346次MRI中54.7%显示活动性炎症,有炎症者治疗升级比例更高(59.3% vs 23.2%)。
  • 64.7%的MRI检查是在患者使用生物制剂/靶向合成DMARDs期间进行的。
  • 140/172(80.1%)患者治疗前MRI有炎症证据。

核心结论

  • MRI可用于评估中轴型脊柱关节炎疾病活动度,且MRI结果直接影响临床治疗决策。
  • 需要进一步研究探讨MRI发现与临床结局之间的关系。

研究设计与样本

  • 共335例患者完成346次MRI扫描,其中301例中轴型脊柱关节炎(170例放射学阳性,131例放射学阴性),31例中轴型银屑病关节炎。
  • 患者以男性为主(60.0%),HLA-B27阳性率60.6%。

主要发现

  • 346次MRI中179次(54.7%)有活动性炎症证据。
  • 有活动性炎症者治疗升级比例为59.3%,无活动性炎症者为23.2%。
  • 224次扫描(64.7%)是在患者使用生物制剂/靶向合成DMARDs期间进行的。
  • 140/172(80.1%)患者治疗前MRI有炎症证据。

临床怎么用

  • MRI可用于评估中轴型脊柱关节炎疾病活动度并辅助临床治疗决策。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of MRI of the spine/sacroiliac joints to aid the diagnosis of axial spondyloarthritis (axSpA) is well established. Limited data, however, exist on the use of MRI to assess disease activity, resulting in current Assessment of SpondyloArthritis International Society (ASAS)/European Alliance of Associations for Rheumatology (EULAR) guidelines not recommending the use of MRI for this purpose. We aimed to assess the current use of MRI to assess disease activity and its impact on clinical decision making. METHODS: As part of a service evaluation, we identified patients with a prior diagnosis of axSpA, who had an MRI of the spine/sacroiliac joints requested between May 2020 and December 2023 at The Leeds Teaching Hospitals Trust (Leeds) and Northwick Park Hospital (London). Clinical and demographic data were extracted from the medical notes. Data on MRI findings were extracted from the radiologist's report. RESULTS: Overall, 346 scans were performed in 335 patients. 301 patients had axSpA (170 radiographic axSpA, 131 non-radiographic axSpA) and 31 axial psoriatic arthritis. Patients were predominantly male (60.0%) and HLA-B27 positive (60.6%). 140/172 (80.1%) of patients had evidence of inflammation on a pre-treatment MRI scan. 224 scans (64.7%) were performed in patients on biologic/targeted synthetic disease-modifying antirheumatic drugs. Of the 346 MRIs performed during the audit period, 179 (54.7%) had evidence of active inflammation and those with active inflammation were more likely to have their treatment escalated (59.3% vs 23.2%). CONCLUSIONS: MRI is of utility in assessing disease activity with results of MRI scans directly influencing treatment decision making at the bedside. Further research exploring the relationship between MRI findings and clinical outcomes is warranted.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Weddell J, Farah A, Shah R, et al. Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres. RMD Open. 2025. PMID: 41107056. doi:10.1136/rmdopen-2025-005925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。